Our annual predictions for 2026 continue with Life Science. Throughout the next few weeks we will be asking the industry experts what they think we will see in 2026. Check back as we cover AI in healthcare, interoperability, patient experience. Value-Based Care, and the business of healthcare.
Read More
By Ellie Gabel – Even as industry professionals have infused digital functionality into countless medical devices, the bandage has remained virtually unchanged. Thanks to AI and the Internet of Things (IoT), it is finally entering the 21st century. With the smart bandage, physicians can continuously monitor wounds to identify complications early.
Our annual predictions for 2026 continue with interoperability. Throughout the next few weeks we will be asking the industry experts what they think we will see in 2026. Check back as we cover AI in healthcare, Life Sciences, patient experience. Value-Based Care, and the business of healthcare.
By Andy Dé – Despite the hype and heavy investment, most organizations are discovering that generative AI is far harder to operationalize than imagined. MIT’s report, The Gen AI Divide: State of AI in Business 2025, reveals that 95% of Gen AI projects fail to reach meaningful production.
By Steven Posnack – It wasn’t always so, but today we have technology available to exchange health information anywhere there’s an internet connection. What’s slowing us from doing so at nationwide scale is trust. The frictions are human and institutional. They cannot be addressed exclusively with technology.
By Scott Anderson – Many behavioral health agencies lack adequate controls to address and recover from a cybersecurity incident. What these agencies need are capabilities such as adequate backup and recovery, managed detection and response, security information and event management, data loss prevention and other key security elements.
By Vicenç Ferrer MBA & Cathy Schwegler – Across the healthcare continuum, clinicians are exploring immersive environments as a tool to ease anxiety, support emotional regulation, and strengthen engagement for individuals living with cognitive decline.
By Arthur Allen – While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the cheaper medicines to get on the market, industry officials say.
Our annual predictions for 2026 continue with AI in healthcare RCM. Throughout the next few weeks we will be asking the industry experts what they think we will see in 2026. Check back as we cover AI in healthcare, interoperability, Life Sciences, patient experience. Value-Based Care, and the business of healthcare.